How Long Does a GLP-1 Take to Work?

In the pivotal trials, weight change separates from placebo at about week 4, keeps falling through roughly week 60, and is measured at its endpoint at 68 to 72 weeks. The first month is a starting dose, not a working dose — which is the single most useful thing to understand before you judge whether the medication is doing anything.

The honest timeline

The clearest picture comes from the FDA-reviewed trial data in the prescribing information itself, because it plots weight change at every measured visit rather than only at the finish line.

In SURMOUNT-1, the 72-week tirzepatide trial in 2,539 adults, the treated groups pull away from placebo by week 4. The curves keep descending until roughly week 60, then flatten. At week 72 the mean reduction from baseline was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo.

In STEP 1, the 68-week semaglutide trial in 1,961 adults, the mean reduction was 14.9% against 2.4% for placebo. Put differently: 83.5% of people on semaglutide lost at least 5% of their body weight, and 47.9% lost at least 15%.

Both sets of figures come from the FDA's own review of the trial data, and both trials were also published in the New England Journal of Medicine — SURMOUNT-1 in 2022 and STEP 1 in 2021.

Why the first month is not a fair test

Neither medication starts at its maintenance dose. Both are titrated upward on a fixed schedule, and that schedule is long.

Semaglutide (Wegovy) starts at 0.25 mg once weekly and steps up every four weeks — 0.5, 1, 1.7 — reaching the 2.4 mg maintenance dose at week 17. That is sixteen weeks of escalation before anyone is on a full dose.

Tirzepatide (Zepbound) starts at 2.5 mg once weekly. The label is blunt about what that dose is for: "The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage." Increases come in 2.5 mg steps no sooner than every four weeks, and reaching the 15 mg maximum takes about 20 weeks.

So someone six weeks in, frustrated that the scale has barely moved, is usually on the second rung of a five-rung ladder. If the dose is escalated more slowly because of nausea — which the label explicitly allows for — the ladder gets longer still.

What is happening before the scale moves

Both medications slow gastric emptying from the first dose. For tirzepatide the label notes the delay "is largest after the first dose and this effect diminishes over time." That is why the earliest changes people notice tend to be about eating rather than weight: meals feel like they end sooner.

Measuring that effect takes controlled conditions, and the published measurements come later than most people expect. In one study, semaglutide 1.0 mg at 12 weeks produced a 24% reduction in total energy intake alongside reduced hunger and cravings. In another, semaglutide 2.4 mg at week 20 cut ad libitum lunch intake by 35% against placebo.

There is no good published answer to "how many days until I feel it." Anyone who gives you a specific number is estimating. What is documented is the mechanism from dose one, and the weight separation from week four.

The week-12 checkpoint, and why a slow start is not a failed one

This is the part worth reading twice.

A 2025 analysis of SURMOUNT-1 split 1,545 tirzepatide-treated participants by their result at week 12. Eighteen percent had lost less than 5% of their body weight by then — the group the paper calls late responders.

By week 72, 90% of those late responders had still reached at least 5% weight reduction. It took them an average of about 25 weeks to get there instead of 12.

Slow early response did not predict failure. It predicted a longer runway. That is a very different conversation from the one most people have with themselves at week 10, and it is the reason a plan gets reassessed rather than abandoned.

What this means for your plan

Revive offers both semaglutide and tirzepatide injections as part of a medically supervised weight management program. Which one is appropriate, at what dose, on what schedule — or whether either is appropriate at all — is a decision for your prescribing clinician, made with your history in front of them.

What a realistic plan looks like: a titration period measured in months rather than weeks, a genuine checkpoint around week 12 to review response and tolerability, and an understanding that the curve in the trial data keeps descending well past the point most people expect it to stop.

Angelica Alcaraz, BSN, RN, will assess your specific needs during your consultation.

Book a Free Consultation